The hepatitis C virus (HCV) is a continuing threat to public health. The systemic administration of interferon alpha with ribavirin is the only currently approved treatment. However, this treatment is associated with a wide spectrum of systemic side effects that limits its effectiveness; thus, there is an urgent need for new treatment modalities. In this study, we describe a novel anti-HCV strategy employing a recombinant transcription factor that we have engineered in such a way that NS3/4a viral protease controls its intracellular localization, thereby restoring interferon secretion specifically in cells infected with HCV. Proof-of-concept experiments validated the strategy, showing that the recombinant transcription factor was triggered to stimulate interferon promoter by NS3/4A and remained inactive in cells without NS3/4a. Using an adenovirusassociated viral vector delivery system, we found that the recombinant transcription factor inhibited HCV replication effectively in vitro in cultured cells.
Hepatitis C virus (HCV) and hepatitis B virus (HBV) are the major public health concerns among the seven hepatitis viruses (A to G) that have been discovered to date. These two viruses are the leading causes of liver cirrhosis and hepatocellular carcinoma worldwide (32) . The incidence of HBV is decreasing because of successful vaccination programs, whereas the development of vaccines against HCV has remained a challenge. HCV, a member of Hepacivirus, of the Flaviviridae virus family, is a single-stranded, positive-sense RNA virus with six main genotypes and 50 subtypes (25) . HCV infects 130 to 170 million people worldwide (2) . Chronic hepatitis develops in 60 to 80% of infected patients, and hepatocellular carcinoma follows in 20% of these during the course of infection (32) . The systemic administration of interferon alpha (IFN-␣) together with ribavirin for 24 weeks is the only approved protocol that reduces mortality (6) . However, infection sometimes recurs after the completion of therapy (18) , and interferon treatment is associated with severe systemic side effects that reduce patient adherence to therapy, require dose modifications, and result in premature patient withdrawal from treatment (26) .
There have been many attempts to develop specific smallmolecule inhibitors of HCV. However, inhibitors often give rise to resistant HCV strains (18, 19) . Resistant strains develop as a result of the great variety of the HCV genetic pool, reflecting the generation of quasispecies through the combined action of error-prone viral RNA polymerase, a high rate of viral replication, and long-term persistent infection (36) . Because most patients already have quasispecies upon diagnosis (10), a new anti-HCV approach is required to complement small-molecule inhibitor strategies. To address this need, we have designed a novel strategy for inducing the local secretion of type I interferon (IFN-␣ and -␤) by HCV-infected cells. We constructed and evaluated a recombinant transcription factor that is localized to mitochondria in an inactive state in the absence of HCV infection. In HCV-infected cells, the transcription factor is activated by the viral protease NS3/4a and stimulates interferon-encoding genes. The systemic side effects of interferon are minimized using this approach, because the interferon concentration is increased only at the site of infection. We have termed this strategy protease-activated transcription to inhibit hepatitis C (PAT-C).
The key transcriptional regulators of type I interferon are interferon regulatory factors 3 (IRF3) and 7 (IRF7) (12, 30) . IRF3 is ubiquitously expressed in many cell types and regulates the immediate-early, specific, and controlled induction of IFN-␤, whereas IRF7 stimulates the late, robust, and multigenic production of the IFN-␣ family, thereby amplifying interferon signaling (20) . The motif requirement for promoter binding is highly specific for IRF3; thus, only IFN-␤ and IFN-␣4 promoters can respond to activated IRF3. However, IRF7 has a less-stringent DNA-binding specificity and thus stimulates the transcription of the entire set of type I interferons (30) . These characteristics make IRF7 more suitable than IRF3 as a template for the construction of the recombinant transcription factor PAT-C. Moreover, IRF7 is not only a master regulator of the type I interferon response but also governs the induction of T-cell responses (12) . In vivo DNA vaccine studies have demonstrated that the cotransfection of IRF7 induces efficient antibody generation and stimulates Tcell responses (5, 33). These observations suggest that the recovery of interferon secretion by IRF7-based PAT-C would help cells mount a proper T-cell response and generate antibodies to HCV proteins.
We used adenovirus-associated virus (AAV) as a gene delivery system to express the recombinant protein in hepatocytes. This gene delivery method is widely used because of its safety and efficiency (11) . Using a helper-free AAV system, it is possible to produce pure replication-deficient virus (27) . Taken together with the fact that AAV is not associated with humans, this makes the AAV system the safest delivery method developed to date (39) . AAV can efficiently deliver a gene of interest to dividing and nondividing cells in a broad range of hosts and can achieve stable and long-term gene expression. These important characteristics of safety and efficiency account for the increased use of AAV vectors in a variety of fields (8) . In this study, we developed the PAT-C strategy, performed a series of proof-of-concept experiments, and generated a recombinant AAV/PAT-C and tested its ability to inhibit the replication of HCV in vitro in cultured cells.
MATERIALS AND METHODS

Cells and virus.
The hepatic cell lines Huh7 and Huh 7.5 were kindly provided by Charles Rice (Rockefeller University, New York, NY). The plasmid pJFH1 (GenBank accession number AB047639) was kindly provided by Takaji Wakita (Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan). 293T, HeLa, Huh7, and Huh7.5 cells were maintained in complete Dulbecco's modified Eagle's medium (DMEM) (Gibco-BRL) containing 10% (vol/vol) fetal bovine serum and 1% (wt/vol) penicillin-streptomycin (Gibco-BRL) at 37°C in a humidified 5% CO 2 incubator (Thermolyne). HCV particles were collected from supernatants of Huh7.5 cells transfected with JFH1 RNA, which was prepared by in vitro transcription from pJFH1, as described elsewhere (40) . Transfectin (Bio-Rad) or calcium phosphate (BD Biosciences) was used for transient transfections.
Cloning. Coding sequences to be cloned into PAT-C first were analyzed for the presence of restriction enzyme recognition sites. A multiple cloning site was synthesized to include restriction sites for AflII, NheI, XbaI, EcoRV, XhoI, SpeI, HindIII, and NotI, which did not cleave within the coding regions of the modules. The synthesized sequence also contained a Kozak sequence, a start codon, and a stop codon. The multiple cloning site of the pIRES vector was replaced with the synthesized DNA, adding an EF promoter and a simian virus 40 (SV40) poly(A) signal. The fragment between the promoter and the poly(A) signal was cloned into the corresponding region of the pRL-CMV vector. The final vector, pCM, was used as a backbone for the cloning of constructs (see Fig. 2 ). The modules were amplified from cloned genes using a high-fidelity PCR kit (Stratagene) and primers designed to amplify sequences corresponding to the following protein regions: amino acids (aa) 2 to 238 of enhanced green fluorescent protein (EGFP) (GenBank accession number U55762); the DNA-binding domain (DBD; aa 2 to 152), activation domain (AD; aa 153 to 246), truncated activation domains (a1, aa 153 to 246; a2, aa 200 to 246; a3, aa 228 to 246), and regulatory domain (RD; aa 468 to 503) of IRF7 (GenBank accession number NM_001572); the mitochondrial localization signal (MLS; aa 500 to 540) of MAVS (mitochondrial antiviral signaling; GenBank accession number NM_020746.3); and the nuclear export signal (NES; aa 75 to 83) of Rev (GenBank accession number NC_001802.1). Each primer contained a 5Ј-terminal restriction site for appropriate cloning, as described in Fig. 2 . Amplified products were purified using a PCR cleanup kit (Qiagen) and incubated with relevant restriction enzymes. Products were gel purified using a gel extraction kit (Qiagen) and ligated into the pCM vector using a quick ligation kit (New England Biolabs). The abbreviations used to denote recombinant proteins are based on combinations of the capital letters representing the following domains: the wildtype DNA-binding domain (D), K92R mutant DNA-binding domain (Dm), activation domain (A), truncated activation domains (a1, a2, a3), and regulatory domain (R) of lRF7; the wild-type mitochondrial localization domain (L) and C508A mutant mitochondrial localization domain (Lm) of MAVS; and the nuclear export domain (E) from the human immunodeficiency virus Rev protein. GDRLmE, PAT-C mT , and PAT-C mD were generated using an oligonucleotidedirected mutagenesis kit (Stratagene) from the corresponding wild-type templates. NS3/4a and nonstructural polyprotein genes were amplified from pJFH1 and cloned into pcDNA5 or EGFP vectors.
Generation and purification of AAV. Recombinant AAVs (rAAVs) were generated using an AAV Helper-free gene delivery and expression system (Stratagene). The cloned pAAV-MCS vector (Fig. 2) was cotransfected with pRepCap and pHelper into 293T cells. After 3 days, cells were lysed by three freeze-thaw cycles, rAAVs were purified by CsCl gradient ultracentrifugation, and the viral titer was measured by quantitative reverse transcription-PCR (qRT-PCR), as described elsewhere (16) . The solution of purified rAAV was divided into small aliquots and frozen at Ϫ80°C before use.
Flow-cytometric analysis. Huh7.5 cells were infected with AAV/GFP of eight serotypes. pRepCap genes for the serotypes used in this study were described previously (15) . Forty-eight hours after infection, cells were trypsinized, washed once with phosphate-buffered saline (PBS), and fixed with 4% paraformaldehyde in PBS. The transduction efficiency (TE) was analyzed by flow cytometry using a FACSCalibur system (Becton Dickinson) and the CellQuest program.
Microscopic observation. For confocal microscopy, HeLa cells were seeded on chambered covered glass (LabTak) at 10 4 cells/well 24 h before transfection. The constructs were transfected with or without the NS3/4a expression plasmid. Cells were stained with Mitotracker (Molecular Probes) 24 h after infection and observed by confocal microscopy (Leica TCS SP2).
Immunoblotting. Cells were harvested and resuspended in lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% [vol/vol] NP-40, protease inhibitor cocktail [Roche]). After incubation at 4°C for 10 min, lysed cells were centrifuged at 12,000 ϫ g for 5 min to pellet cell debris. Lysates were resuspended in SDS sample buffer (Sigma), separated by SDS-polyacrylamide gel electrophoresis, and transferred to a polyvinylidene difluoride membrane (Roche). The membrane was blocked with phosphate-buffered saline-0.1% Tween 20 (PBST) containing 5% (wt/vol) powdered skim milk for 30 min and then incubated with a goat anti-GFP primary antibody (Santa Cruz Biotechnologies, Santa Cruz, CA) for 1 h. After being washed three times with PBST, the membrane was incubated with horseradish peroxidase-conjugated secondary antibody (rabbit anti-goat IgG; Santa Cruz Biotechnologies) for 1 h and washed three times with PBST. Specific signals were detected using an enhanced chemiluminescence (ECL) system (Pierce) and an ECL instrument (Fugi; model LAS-4000).
Luciferase assay and ELISA. 293T cells were seeded into 24-well plates at 10 5 cells/well 24 h before transfection. Cells were transfected with an IFN-␣4 promoter-firefly luciferase reporter pGL3 construct and the control renilla luciferase plasmid, pRL-SV40 (Promega). Twenty-four hours after transfection, luciferase activity was measured with a luminometer (Berthold) using a dual luciferase assay kit (Promega) and expressed relative to renilla luciferase activity to normalize for transfection efficiency. Enzyme-linked immunosorbent assays (ELISAs) were performed using a VeriKine human IFN-␣ ELISA kit by following the manufacturer's instructions (PBL Interferon Sources). Quantitative real-time RT-PCR. Supernatants were collected and HCV genomic RNA was extracted using a QIAamp viral RNA mini kit (Qiagen). Viral mRNA copy number was measured by quantitative real-time reverse transcription-PCR using a primer and probe set that targeted regions in the 5Ј-untranslated region (5ЈUTR) sequence. Primers and probe sequences were as follows: forward primer, 5Ј-CGGGAGAGCCATAGTGG-3Ј; reverse primer, 5Ј-AGTA CCACAAGGCCTTTCG-3Ј; and probe, 6-carboxyfluorescein-5Ј-CTGCGGAA CCGGTGAGTACAC-3Ј-Dabcyl. Reverse transcription and PCR were performed in a single tube using UltraSense (Qiagen). qRT-PCR was performed in an Opticon 2 (Bio-Rad) instrument using the following cycling parameters: 50°C for 15 min (reverse transcription), 95°C for 2 min (initial denaturation), and 40 cycles of 95°C for 20 s and 62°C for 1 min, followed by plate reading.
RESULTS
PAT-C strategy. HCV encodes a single polyprotein, which is proteolytically processed into functional proteins by cellular and viral proteases. The viral protease NS3/4a, in particular, is indispensable for the processing and formation of replication complexes (9) (Fig. 1, arrow a) . Retinoic acid-inducible gene I (RIG-I), a pattern-recognition receptor molecule of the RNA helicase family, recognizes the exposed viral RNA and activates MAVS (14) . MAVS is a key interferon signaling mediator localized to the outer membrane of mitochondria; upstream signals converge on MAVS and downstream signals diverge from MAVS (31). Activated MAVS stimulates several downstream molecules, activating a signaling cascade that results in the transcription of interferon genes and the blockade of viral replication (34) . To survive, HCV has evolved mechanisms to block the interferon-signaling pathway. NS3/4a cleaves MAVS at the C508 residue, causing MAVS to dissociate from the mitochondrial membrane ( Fig. 1, arrow b) . This abolishes the signaling function of MAVS and allows HCV to replicate without triggering interferon secretion (28) . Our anti-HCV strategy, based on an engineered PAT-C protein composed of transcription, trigger, and safety modules, exploits this cleavage function of NS3/4a (Fig. 1, box) . The trigger and safety modules localize the PAT-C protein to mitochondria in cells without HCV infection. Importantly, however, the PAT-C protein is designed to be activated by NS3/4a in HCV-infected cells; the cleavage of PAT-C by NS3/4a within the trigger module (Fig. 1, arrow c) releases the transcription module, allowing it to enter the nucleus and stimulate interferon promoters.
PAT-C protein modules. The trigger module is key to the activation of the PAT-C protein. Serial truncation mutants of MAVS, N-terminally tagged with GFP, were tested for the trigger module. A C-terminal segment (aa 500 to 542) was selected as the trigger module because it satisfied the following characteristics (data not shown): mitochondrial localization of GFP, cleavage by NS3/4a, no interference with the nuclear localization of the dislocated GFP, and no interference in normal interferon signaling. The transcription module was a constitutively active mutant of IRF7 made by deleting the IRF7 inhibitory domain (23), a maneuver that circumvents the requirement for phosphorylation by the serine/threonine IB kinases IKKε and TBK1, which normally activate IRF7 (35) . The safety module was a 10-amino-acid peptide sequence (LPPLERLTL) of the human immunodeficiency virus Rev protein. It is a well-characterized leucine-rich NES with the consensus motif LX 1-3 LX 2-3 LXL (24) that prevents the PAT-C protein from entering the nucleus, even if the protein is not anchored to mitochondria.
Three groups of recombinant proteins were designed and constructed to test the PAT-C strategy ( Fig. 2 and Table 1 ). Group I was used for proof-of-concept experiments, group II was designed to enhance the activity of the transcription module, and group III was used for testing antiviral effects against HCV in vitro in cultured cells. Group I constructs were Nterminally tagged with GFP to visualize protein localization and intentionally lacked the activation domain, which prevented the expression of protein at levels sufficient to assay. The abbreviations used in naming constructs are described in the cloning section of Materials and Methods. The names of the constructs and their characteristics are summarized in Table 1 for quick reference.
FIG. 1. Role of NS3/4a in HCV replication and the PAT-C strategy. Arrow a indicates NS3/4a in the formation of replication complexes. A single polyprotein of HCV is processed into functional components. Cellular signal peptidases process structural proteins (Core, E1, and E2), whereas cis-acting viral proteases NS2 and NS3/4a process nonstructural proteins (NS2, NS3, NS4a, NS4b, NS5a, and NS5b). NS3/4a in particular is indispensable for the formation of replication complexes in a membranous web. Arrow b indicates NS3/4a in the blocking of interferon signaling. RIG-I recognizes the exposed viral RNA and activates MAVS. MAVS activates multiple downstream transcription factors, including IRF3. However, NS3/4a cleaves MAVS, releasing it from mitochondria and blocking the interferon-signaling cascade. Arrow c indicates NS3/4a in the PAT-C strategy. A PAT-C protein is composed of transcription, trigger, and safety modules (box). The PAT-C protein is localized to mitochondria by the trigger and safety modules in a cell without HCV infection. However, the transcription module is released from the trigger and safety modules in an HCV-infected cell by virtue of NS3/4a cleavage at the N terminus of the trigger module. The released transcription module enters the nucleus, where it binds interferon promoter sequences and stimulates interferon transcription.
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Proof of concept.
HeLa and 293T cells were used in proofof-concept experiments to validate module functions. We used an NS3/4a expression plasmid in these experiments because in vitro HCV replication currently is possible only in Huh7-based cell lines such as Huh 7.5. Confocal microscopy was used to observe changes in localization caused by NS3/4a in HeLa cells (Fig. 3a) . GFP and GDR were distributed evenly throughout cell, and GDRE was localized to the cytosol. The colocalization of these constructs with mitochondria was not observed, and there were no changes in localization upon NS3/4a expression because the trigger module was absent. GDRL and GDRLE localized to mitochondria and were released from mitochondria by NS3/4a expression. Unlike GDRLE, GDRL m E localized to mitochondria even with NS3/4a expression, because the NS3/4a target residue was mutated. To exclude the possibility of cell specificity and test the antiviral potential in a HCV permissive cell system, these changes were confirmed again in 293T and Huh 7.5 cells (data not shown). The cleavage of the group I constructs by NS3/4a was assessed by immunoblotting (Fig. 3b) . NS3/4a did not cleave GFP, GDR, or GDRE. The rapidly migrating bands observed in GDRL, GDRLE, and GDRL m E lanes might represent the GFP-tagged transcription module cleaved by NS3/4a, because the size was identical to that of GDR. The uncut form was much more prominent in the GDRL m E lane than in the GDRLE lane, reflecting the decreased efficiency of GDRL m E as a substrate for NS3/4a. Because GFP tagging sometimes leads to nonspecific bands, we reconfirmed the cleavage profile using an anti-IRF7 antibody (Fig. 3c ). These data demonstrate that the trigger module was cleaved specifically by NS3/4a. To quantify transcriptional activities, we employed an IFN-␣4 promoter-luciferase reporter construct (Fig. 3d) . GFP was used as a negative control. We found that GDR stimulated the promoter regardless of NS3/4a status; GDRL stimulated the promoter only when NS3/4a was expressed, and GDRE measurably stimulated the promoter but showed no increase in stimulation following the expression of NS3/4a. These data show that the NES alone was not sufficient to block the entrance of the transcription module into the nucleus. GDRLE remained silent when expressed alone and stimulated the promoter only in the presence of NS3/4a, and GDRL m E was not an effective stimulator, even after the expression of NS3/4a. We had two goals in mind in designing the PAT-C strategy. One was the robust stimulation of interferon transcription in cells infected with HCV; the other was the suppression of stimulation in noninfected cells. To more directly compare the different constructs in this context, we measured the ratio of stimulation in the presence and absence of NS3/4a (Fig. 3e) . Only GDRL and GDRLE showed strong stimulation by NS3/ 4a, whereas the ratios for GFP, GDR, GDRE, and GDRLmE were approximately in unity. We conclude that the trigger and safety modules functioned effectively, although NES function was less important than MLS function in preventing transcription in the absence of NS3/4a.
HCV inhibition test. The transcription module used in the experiments described above had minimal enhancer activity, a modification that was required to obtain an adequate level of expression for the assays (Fig. 2, group I) . However, the acti- a The simple names for group III constructs were used to make notations easier to understand. The original abbreviations are described after the names.
FIG. 2. Schematic representation of PAT-C functional modules.
Group I constructs were used in proof-of-concept experiments, group II constructs were used to fine-tune the transcription module, and group III constructs were used in tests of HCV in vitro in cultured cells (GFP, green fluorescent protein; DBD, DNA-binding domain; AD1, activation domain 1; AD2, activation domain 2; RD, regulatory domain; MLS, mitochondrial localization signal; NES, nuclear export signal). The abbreviations for recombinant proteins are described in the cloning section of Materials and Methods. The letter "A" on GDRL m E and PAT-C mT represents the Cys-to-Ala point mutation at the residue targeted by NS3/4a. The letter "R" on PAT-C mD represents the Lys-to-Arg point mutation, which abolishes DNA binding. PAT-C is the fully functional PAT-C protein. vation domain is required to stimulate promoters embedded in a packed chromosomal structure (22) . In addition to including the original activation domain, we tested the inclusion of a second activation domain in the transcription module (Fig. 2 , group II) to obtain stronger enhancer activity. Among the serially truncated second activation domains tested, DAa 1 RLE was the most effective in stimulating the promoter (Fig. 4a) and was incorporated into the transcription module used to test antiviral effects in an HCV culture system (Fig. 2, group  III) . The constructs tested were PAT-C act , which contained a transcription module only; PAT-C, a fully functional PAT-C protein containing all modules; PAT-C mT , which was the same as PAT-C except for the presence of a Cys-to-Ala point mutation at the residue targeted by NS3/4a; and PAT-C mD , which was the same as PAT-C except for the presence of a Lys-to-Arg point mutation to abolish DNA binding (7) . There is a possibility that overexpressed NS3/4a generated by the NS3/4a expression plasmid used in previous experiments functions differently from NS3/4a processed from HCV polyprotein during HCV replication. To address this possibility, we built an HCV polyprotein expression plasmid to mimic polyprotein processing during replication. The secretion of IFN-␣ from 293T cells in response to an HCV nonstructural polyprotein (HCVns), which was processed into multiple viral components, including NS3/4a, then was measured (Fig. 4b) . The positive control, PAT-C act , induced a high level of IFN-␣ secretion regardless of HCVns status. However, the negative controls, PAT-C mD and PAT-C mT , did not induce IFN-␣ secretion in the presence or absence of HCVns. PAT-C induced a high level of interferon secretion in the presence HCVns but did not induce secretion in the absence of HCVns. These results demonstrate that the induction of biologically active IFN-␣ secretion by PAT-C requires the action of the viral protease NS3/4a derived from the proteolytic processing of the viral polyprotein. The multigenic stimulation of interferons and ISG15 was confirmed by qRT-PCR using PAT-C and HCVns in Huh7.5 cells (data not shown).
To test antiviral activities, we transfected group III constructs into Huh7.5 cells and then infected cells with HCV 24 h later (Fig. 4c) . At all time points, viral titers were highest in cells transfected with PAT-C mD , the negative control for transcription containing a point mutation in the DNA-binding domain. The titers were lowest at all time points in cells transfected with PAT-C act , because this construct induced uncontrolled IFN-␣ secretion. PAT-C efficiently inhibited the replication of HCV, whereas PAT-C mT was less effective because the residue targeted by NS3/4a was mutated.
Generation of AAV/PAT-C and in vitro tests of HCV replication inhibition. The plasmid-based gene delivery strategy used in the previous assays is difficult to apply in a therapeutic setting because of its low transfection efficiency and short duration of expression. To express PAT-C in hepatocytes, we applied an rAAV-based gene delivery system, first testing the delivery efficiencies of a GFP gene into Huh7.5 cells using eight serotypes of AAV (1, 2, 2s, 3, 4, 5, 6, and 8 ). Huh7.5 cells were infected with rAAVs and GFP signals were measured by fluorescent-activated cell sorter (FACS) analysis. Serotype 2, with an 86.1% positive rate, was the most efficient (Fig. 5a) , and it was used to generate a recombinant AAV/PAT-C virus in a helper-free AAV production system. We cloned PAT-C and PAT-C mD into pAAV-MCS to generate AAV/PAT-C, the final therapeutic virus, and AAV/PAT-C mD , the negative-control virus (Fig. 2) . Because the single-stranded rAAV gene must be converted into double-stranded DNA, it takes time for a cloned gene to be expressed after infection with rAAV. Therefore, we first tested the ability of rAAVs to prevent HCV infection. Huh7.5 cells prepared at low confluence were infected with AAV/PAT-C or AAV/PAT-C mD 2 days before HCV infection. Media were changed only once 24 h after HCV infection to maximize the effects of PAT-C during the experiment. Titers of HCV released into the media were measured at designated time points before the buffering capacity of the (Fig. 2) were transfected into 293T cells with or without NS3/4a expression plasmids. Minimal amounts of DNA (1 ng of NS3/4a expression plasmid, 2 ng of constructs, 50 ng of the IFN-␣4 promoter construct, and 1 ng of pRLSV40) were used to mimic physiologic conditions. Luciferase activities were assessed after 12 h. The data are presented as the means Ϯ standard deviations of three experiments. (b) IFN-␣ secretion induced by the PAT-C protein. Group III constructs (Fig. 2) were transfected into 293T cells with or without the HCV nonstructural polyprotein (HCVns) expression plasmid. Secreted IFN-␣ levels in supernatants were measured after 24 h by ELISA. The data are presented as the means Ϯ standard deviations from three experiments. (c) Anti-HCV effect of the PAT-C protein. Huh7.5 cells were subcultured in 12-well plates to 20% confluence the day before transfection. Group III constructs (Fig. 2) were transfected using Transfectin. Cells were infected with HCV (1 ϫ 10 6 copies/ml) 4 h after transfection, and media were changed after 24 h. Supernatants were collected 2, 6, and 7 days after infection; viral RNA was extracted and qRT-PCR was performed to measure the copy number of HCV genes. The data are presented as the means Ϯ standard deviations from three experiments.
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on October 15, 2017 by guest http://aac.asm.org/ media was depleted. HCV titers were decreased by AAV/ PAT-C pretreatment; in contrast, titers increased with time following pretreatment with AAV/PAT-C mD (Fig. 5b ). Finally, we tested the effect of rAAVs on cells previously infected with HCV. In these experiments, Huh7.5 cells were infected with AAV/PAT-C or AAV/PAT-C mD 3 days after HCV infection. Media were replaced with fresh media at 2-day intervals until cells had grown to maximum confluence, and the titers of HCV in collected media were determined by qRT-PCR (Fig. 5c) . AAV/PAT-C treatment suppressed the increase in viral titers, but in cells infected with AAV/PAT-C mD , viral titers increased sharply over time. These results demonstrate that AAV/PAT-C exerted antireplication effects on an ongoing HCV infection.
DISCUSSION
Type I interferons are the major cytokines involved in eliminating HCV infection. However, when systemically administered, interferons produce side effects that limit their effective application. The restoration of the local secretion of interferon from HCV-infected cells by the engineered PAT-C protein described here could minimize side effects by reducing systemic interferon levels. The trigger and safety modules of this protein proved critical to accomplishing this goal. GDR showed the stimulation of the interferon promoter without NS3/4A (Fig. 3d) , and PAT-C act induced a high level of interferon secretion without the HCV polyprotein (Fig. 4b) . Although PAT-C act exerted a maximal anti-HCV effect in vitro, this constitutively active construct could not be applied in vivo due to the uncontrolled secretion of interferon and attendant systemic side effects. The trigger and safety modules maintained the inactive status of GDRLE by preventing it from entering the nucleus (Fig. 3a) . In the absence of NS3/4A expression, GDRLE stimulated only basal levels of interferon promoter activity (Fig. 3d) , and without HCV polyprotein processing, PAT-C did not induce detectable interferon secretion from cells (Fig. 4b) . We attempted to measure the levels of secreted IFN-␣ by group III constructs in Huh7 and Huh7.5 cells. However, the levels of IFN-␣ were below the detection limit of the ELISA, except in the case of the positive control, PAT-C act . From this we conclude that the level of interferon produced, though undetectable by conventional assays, exceeded the minimum level needed to inhibit HCV replication. The production of AAV/PAT-C reconfirmed the specific activation of PAT-C by NS3/4A. Using a helper-free AAV production system, we were able to obtain almost the same viral titer with AAV/PAT-C as we were with AAV/PAT-C mD (data not shown), indicating that there was no stimulation of interferon by PAT-C. In contrast, we were unable to obtain AAV/ PAT-C act because of its uncontrolled stimulation of interferon in packaging cell lines.
There are genotype-dependent differences in the response to interferon. About 50% of patients infected with genotype 1 do not respond well to interferon therapy. We did not test the effect of AAV/PAT-C on genotype 1 because a genotype 1 culture system currently is unavailable. However, local interferon secretion by AAV/PAT-C might trigger an adaptive immune response toward the HCV protein in addition to inhibiting HCV replication. A unique feature of HCV infection is that viral replication outpaces the slow host adaptive immune response, allowing sufficient time for quasispecies to appear (32) . The impairment of adaptive immune responses might result from the failure of HCV-infected cells to secrete interferon, reflecting the important role of interferon in bridging innate immunity and adaptive immunity, such as in the maturation of dendritic cells and antigen presentation (14) . Many lines of evidence support the notion that an adequate T-cell response is a prerequisite for the successful eradication of HCV infection (3, 4, 37) . The role of NS3/4a in the pathogenesis of chronic HCV infection has been demonstrated in a clinical setting (21, 38) . Collectively, these data suggest that the innate immune response in cells infected with HCV is important for proper adaptive immunity. Therefore, the restoration of interferon secretion from cells infected with HCV might help trigger an adaptive immune response toward HCV proteins.
GFP-tagged MAVS protein has been used in HCV research for the visual confirmation of viral replication. Recently, a system for monitoring HCV replication was developed by exploiting MAVS cleavage by NS3/4a (13) . We extended the application of this cleavage event to an antiviral strategy. It was reported that the Cys-to-Ala point mutation at residue 503 in MAVS abolished cleavage by NS3/4a. In our confocal microscopy experiments, GDRL m E, which incorporated this mutation in the trigger module, showed no cleavage by NS3/4a (Fig.  3a) . However, immunoblot assays revealed that the mutation did not completely block the cleavage of GDRL m E, although it did reduce the ability of GDRL m E to serve as a substrate for NS3/4a (Fig. 3b and c) . We could not conclude whether this incomplete block resulted from the recombination of MAVS. However, it could explain why the anti-viral effects of PAT-C and PAT-C mT were little different in experiments in which genes were delivered using the transfection reagent Transfectin (Fig. 4c) . Because the transduction efficiency of Transfectin was less than 10% when applied to Huh7.5 cells (data not shown), the probability that cells were both transfected with constructs and infected by HCV is low. Therefore, the differences in antiviral effects between PAT-C and PAT-C mT were not as dramatic as those between PAT-C and PAT-C act , because PAT-C act stimulated interferon secretion regardless of HCV coinfection.
Many anti-HCV drug development strategies target NS3/4a for inhibition. Although the restoration of interferon signaling by the inhibitor blocks HCV replication, it usually encounters resistance (18) or increasing dosage requirements (21) . With the PAT-C strategy, we took the opposite approach, exploiting the function of NS3/4A rather than inhibiting it. A virus with a mutation in NS3/4a that does not cleave the PAT-C protein cannot survive, because NS3/4a is indispensable for the formation of viral replication complexes (9) and the blocking of host interferon signaling (28) . Therefore, the PAT-C strategy could be applied in cases of resistance to an NS3/4a inhibitor. Although many gene therapeutic approaches using rAAV are undergoing clinical trials (8) , there are some issues that must be taken into account in considering the clinical application of the PAT-C strategy. One report noted that the systemic injection of rAAV leads to cytotoxic T lymphocyte (CTL)-mediated lysis of transfected cells by antibodies generated by memory T cells (29) . This concern could be overcome by changing the route of administration by, for example, using ultrasoundguided portal vein injection. The modification of the immunogenic epitope of the capsid gene is another possible solution to this problem. There also could be a safety issue surrounding the use of an NES originating from HIV. However, the sequences could be mutated silently or replaced by an NES of human origin. The function of AAV/PAT-C should be evaluated in animal studies before being considered for clinical trials. However, no suitable small-animal model is currently available. A SCID mouse model is not adequate for our purposes because intact adaptive immunity, which is lacking in these mice, is a requirement for triggering the adaptive immunity to HCV by AAV/PAT-C. Our current efforts are directed toward developing an animal model using the tree shrew, which was recently reported to be a natural host for HCV (1, 41, 42) .
The resistance to small molecular inhibitors is a major hurdle in the development of antibiotics to RNA viruses because of the high rates of mutation characteristic of these viruses. New therapeutic approaches for overcoming this problem are currently in development. One such recent report described controlling host factors that might be used to inhibit influenza viral replication (17) . A small RNA virus must pack many genes into a genome of limited size. To accomplish this, many small RNA viruses have evolved to encode a single polyprotein that is processed by cellular and viral proteases. The presence of a specific viral protease is a unique discriminator between noninfected and infected cells, one that is not unique to HCV. Thus, by replacing the trigger module with a specific target domain of a viral protease and changing the DBD of the transcription module to induce the expression of a specific gene product that inhibits viral replication, the PAT-C strategy can be adapted to any virus whose life cycle depends on the function of a viral protease.
